Abstracts tagged "tocilizumab and treatment"

Abstract Number: 578 • 2018 ACR/ARHP Annual Meeting
Effect of Disease Duration and Other Patient Baseline Characteristics on Outcomes in Tocilizumab-Treated Rheumatoid Arthritis Patients: A Pooled Analysis
Andrea Rubbert-Roth¹, Daniel Aletaha², Jenny Devenport³, Paris N. Sidiropoulos³, Yves Luder⁴, Michael Edwardes⁵ and Johannes W. G. Jacobs⁶, ¹Kantonsspital St Gallen, St Gallen, Switzerland, ²Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ³Genentech, Inc., South San Francisco, CA, ⁴F. Hoffmann-La Roche, Basel, Switzerland, ⁵Everest Clinical Research, Markham, ON, Canada, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands
Background/Purpose: Tocilizumab (TCZ) efficacy and safety in rheumatoid arthritis (RA) have been well established by numerous phase 3 and 4 studies and observational studies. The…
Abstract Number: 898 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3 Randomized Controlled Trial
Dinesh Khanna¹, Celia J. F. Lin², Masataka Kuwana³, Yannick Allanore⁴, Anastas Batalov⁵, Irena Butrimiene⁶, Patricia Carreira⁷, Marco Matucci Cerinic⁸, Oliver Distler⁹, Dusanka Martinović Kaliterna¹⁰, Carina Mihai¹¹, Mette Mogensen¹², Marzena Olesinska¹³, Janet E. Pope¹⁴, Gabriela Riemekasten¹⁵, Tatiana S. Rodriguez-Reyna¹⁶, Maria José Santos¹⁷, Jacob van Laar¹⁸, Helen Spotswood¹⁹, Jeffrey Siegel², Angelika Jahreis², Daniel E. Furst²⁰ and Christopher P. Denton²¹, ¹University of Michigan, Ann Arbor, MI, ²Genentech, Inc., South San Francisco, CA, ³Nippon Medical School, Tokyo, Japan, ⁴Cochin Hospital, Paris Descartes University, Paris, France, Paris, France, ⁵Medical University of Plovdiv, Plovdiv, Bulgaria, ⁶Rheumatology Clinic, Medical Faculty, Vilnius University, Vilnius, Lithuania, ⁷Servicio de Reumatología, Hospital Universitario, Madrid, Spain, ⁸University of Florence, Florence, Italy, ⁹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹⁰University of Split, Split, Croatia, ¹¹Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ¹²Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ¹³National Institute of Geriatrics, Rheumatology and Rehabilitation,, Warsaw, Poland, ¹⁴Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁵Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ¹⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹⁷Serviço de Reumatologia do Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ¹⁸University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Roche Products Ltd., Welwyn Garden City, United Kingdom, ²⁰University of California Los Angeles, Los Angeles, CA, ²¹University College London, London, United Kingdom
Background/Purpose: The anti–interleukin-6 (IL-6) receptor-alpha antibody tocilizumab (TCZ) demonstrated numeric improvement in skin thickening (modified Rodnan skin score [mRSS]) and clinically meaningful lung function preservation…
Abstract Number: 2938 • 2018 ACR/ARHP Annual Meeting
Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (ACR CRISS) in a Phase 3 Randomized Controlled Trial
Dinesh Khanna¹, Celia J. F. Lin², Helen Spotswood³, Jeffrey Siegel², Angelika Jahreis², Christopher P. Denton⁴ and Daniel E. Furst⁵, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Genentech, Inc., South San Francisco, CA, ³Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁴University College London, London, United Kingdom, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Treatment with the IL-6 receptor inhibitor tocilizumab (TCZ) in early progressive systemic sclerosis (SSc; focuSSced trial; NCT02453256) resulted in numeric improvements in skin sclerosis…
Abstract Number: 1613 • 2016 ACR/ARHP Annual Meeting
Safe and Effective Tocilizumab Therapy in Elderly Patients with Rheumatoid Arthritis
Christof Specker¹, Jörg Kaufmann², Herbert Kellner³, Peter Kaestner⁴, Christoph Volberg⁵, Verena Braunewell⁶, Martin Aringer⁷, Maren Sieburg⁸, Lothar Meier⁹, Michael Hofmann¹⁰, Jan-Paul Flacke¹¹, Hans-Peter Tony¹² and Gerhard Fliedner¹³, ¹Rheumatology & Clinical Immunology, University Hospital Essen, Essen, Germany, ²Ambulant Centres for Rheumatology, Ludwigsfelde, Germany, ³Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁴Outpatient department of Rheumatology, MVZ Ambulantes Rheumazentrum, Erfurt, Germany, ⁵Rheumazentrum Neuss, Neuss, Germany, ⁶Schwerpunktpraxis Rheumatologie, Moenchengladbach, Germany, ⁷Rheumatology, Medicine III, University Clinical Center Technical University of Dresden, Dresden, Germany, ⁸Rheumatologische Gemeinschaftspraxis, Magdeburg, Germany, ⁹Gemeinschaftspraxis für Innere Medizin - Rheumatologie, Hofheim am Taunus, Germany, ¹⁰Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ¹¹Rheumatology, Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹²Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ¹³Internal Med/Rheumatology, Rheumatological Practice, Osnabrueck, Germany
Background/Purpose: The non-interventional study ICHIBAN was set up in 2010 to evaluate the effectiveness and safety of intravenously administered Tocilizumab (TCZ IV) in patients (pts)…
Abstract Number: 2521 • 2016 ACR/ARHP Annual Meeting
Lower Baseline 14-3-3η Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients
Shintaro Hirata¹, Anthony Marotta², Kentaro Hanami¹ and Yoshiya Tanaka³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Augurex Life Sciences Corp., Vancouver, BC, Canada, ³University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Serum 14-3-3η is a mechanistic marker that is involved in the pathogenesis of RA and is a potent up-regulator of IL-6. We previously reported…
Abstract Number: 265 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Compared with Anakinra in Refractory Adult-Onset Still’s Disease. Multicenter Study of 75 Patients
Leyre Riancho-Zarrabeitia¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Jose L. Hernández², Francisco Ortiz-Sanjuán¹, Alejandro Olivé³, Anne Riveros Frutos⁴, Santos Castañeda⁵, Javier Narváez⁶, Maria Luisa Velloso Feijoo⁷, M. Victoria Hernández⁸, Alberto Sifuentes Giraldo⁹, Olga Maiz-Alonso¹⁰, Esteban Rubio Romero¹¹, Cristina Mata-Arnaiz¹², Adela Gallego Flores¹³, Jordi del Blanco¹⁴, Catalina Gómez-Arango¹⁵, Sara Manrique-Arija¹⁶, Maria Carmen Ordoñez¹⁷, Inmaculada Ros Vilamajo¹⁸, Miguel Angel Caracuel-Ruiz¹⁹, Mercedes Freire²⁰, Jose Llobet²¹, Carlos Marras²², Concepción Moll Tuduri²³, Chamaida Plasencia²⁴, Rosa Roselló²⁵, Ana Urruticoechea²⁶, Inmaculada Jiménez-Moleón²⁷, José Antonio Bernal²⁸, Vera Ortiz-Santamaría²⁹, Juan Ramón De Dios³⁰, Mireia Moreno³¹, Jordi Fiter³², Marina de los Riscos³³, Patricia E. Carreira³³, María José Rodríguez Valls Sr.³⁴, Carmen Gonzalez-Vela³⁵, Javier Loricera¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Rheumatology, Hospital U German Trias i Pujol, Badalona, Spain, ⁴Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁵Rheumatology, H.U. La Princesa, Madrid, Spain, ⁶Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷H Valme, Sevilla, Spain, ⁸Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, ⁹Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹⁰Rheumatology, HU Donostia, San Sebastián, Spain, ¹¹Rheumatology Department,, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹²Rheumatology, Hospital Laredo, Santander, Spain, ¹³Rheumatology, Hospital de Mérida, Mérida, Spain, ¹⁴Rheumatology, H Sant Jaume, Calella, Spain, ¹⁵Rheumatology, Hospital Basurto,, Santander, Spain, ¹⁶Rheumatology, Hospital Universitario Carlos Haya, Malaga, Spain, ¹⁷HRU Carlos Haya, Malaga, Spain, ¹⁸Hospital Son Llàtzer, Palma de Mallorca, Spain, ¹⁹Plaza Cruz Roja, 1, Hospital Reina Sofia, Córdoba, Spain, ²⁰Hospital Universitario Juan Canalejo, La Coruña, Spain, ²¹Hospital San Pau, Barcelona, Spain, ²²Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ²³H Mateu Orfila, Mahón, Spain, ²⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ²⁵H San Jorge, Huesca, Spain, ²⁶Hospital Can Misses, Ibiza, Spain, ²⁷Rheumatology, Hospital San Cecilio, Granada, Spain, ²⁸Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²⁹Rheumatology, Hospital General. Granollers., Granollers, Spain, ³⁰Rheumatology, HU Álava, Vitoria, Spain, ³¹Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain, ³²Rheumatology, HU Son Espases. Palma de Mallorca., Palma de Mallorca, Spain, ³³Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ³⁴Rheumatology, Rheumatolgy Unit. Hospital Jerez, Jerez, Spain, ³⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Interleukin (IL)-1 and IL-6 are pivotal cytokines in the pathogenesis of adult-onset Still’s disease (AOSD). Our aim was to compare the efficacy and safety of…
Abstract Number: 1340 • 2015 ACR/ARHP Annual Meeting
Value of 18F-FDG PET for Therapeutic Assessment in Patients with Polymyalgia Rheumatica Treated in First Line By Tocilizumab
Xavier Palard¹, Solene Querellou², Maelenn Gouillou³, Alain Saraux^4,5, Thierry Marhadour⁶, Florent Garrigues⁷, Ronan Abgral⁸, Pierre-Yves Salaun⁸ and Valerie Devauchelle^9,10, ¹Department of nuclear medicine, University hospital of Brest, Brest, France, ²Department of nuclear medicine, Université Européenne de Bretagne; Université de Brest; EA3878 (GETBO) IFR148, Brest, French Polynesia, ³Clinical Investigation Centre (CIC) 1412, CHU Cavale Blanche- Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France, ⁴Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶CHU La Cavale Blanche, Brest, France, ⁷Radiology department, Cavale Blanche Hospital and Brest Occidentale University, Brest, France, ⁸Department of nuclear medicine, Université Européenne de Bretagne; Université de Brest; EA3878 (GETBO) IFR148, Brest, France, ⁹Service de Rhumatologie, CHU Brest, Brest, France, ¹⁰Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France
Background/Purpose: To evaluate the interest of 18F-FDG positron emission tomography-computed tomography (PET-CT) for therapeutic assessment in polymyalgia rheumatica (PMR) patients undergoing tocilizumab (TCZ) therapy at first…
Abstract Number: 1987 • 2015 ACR/ARHP Annual Meeting
Dramatic Efficacy of Tocilizumab As First Line Therapy in Patients with Recent Polymyalgia Rheumatica (PMR): Results of the First Longitudinal Prospective Study
Valerie Devauchelle¹, Alain Saraux², Jean-Marie Berthelot³, Divi Cornec⁴, Yves Renaudineau⁵, Sandrine Jousse-Joulin¹, Thierry Marhadour⁶, Solene Querellou⁷, Florent Garrigues⁸, Michel De Bandt⁹ and Maelenn Gouillou¹⁰, ¹Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, ²Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ³Rheumatology, University Hospital, Nantes, France, ⁴Department of rheumatology, Brest Occidentale University, Brest, France, ⁵Immunology, Brest University Medical School Hospital, Brest, France, ⁶CHU La Cavale Blanche, Brest, France, ⁷Nuclear Medicine Department, Morvan University Hospital, Brest, France, ⁸Radiology department, Cavale Blanche Hospital and Brest Occidentale University, Brest, France, ⁹Rheumatology department, CHU Fort de France, Fort de France, France, ¹⁰Clinical Investigation Centre (CIC) 1412, CHU Cavale Blanche- Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France
Background/Purpose: Glucocorticoids (GCs) are the cornerstone treatment of polymyalgia rheumatica (PMR) but induce several adverse events. Methods: Objectives: To evaluate efficacy and safety of tocilizumab…
Abstract Number: 2505 • 2014 ACR/ARHP Annual Meeting
Long-Term Treatment with Tocilizumab (TCZ) Strongly Suppresses Joint Destruction in Biologic-naïve Patients with Rheumatoid Arthritis (RA) Regardless of Inflammation Status
Akira Sagawa, Sagawa Akira Rheumatology Clinic, Sapporo,060-0001, Japan
Background/Purpose: It is still difficult to completely prevent the progression of joint destruction with any of the currently available biologics. It has been reported that…
Abstract Number: 2509 • 2014 ACR/ARHP Annual Meeting
ADAM-10 As a Tocilizumab Treatment Predictive Factor in Rheumatoid Arthritis
Takeo Isozaki, Sakiko Isojima, Takahiro Tokunaga, Masayu Umemura, Hidekazu Furuya, Ryo Yanai, Ryo Takahashi, Kuninobu Wakabayashi, Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose :A disintegrin and metalloproteinases (ADAMs) are a family of transmembrane and secreted proteins. ADAM-10 has been reported to be the enzyme responsible for the…
Abstract Number: 368 • 2014 ACR/ARHP Annual Meeting
Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis
Anne C. Bay-Jensen¹, Anne Sofie Siebuhr², Inger Byrjalsen³, Claus Christiansen³ and Morten Asser Karsdal¹, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is partly characterized by joint destruction. Personalized health care is needed in RA to enable i) prediction of those patients that…
Abstract Number: 375 • 2014 ACR/ARHP Annual Meeting
Evaluation of RAPID3 with Minimal Joint Count and ACR/EULAR Provisional Remission Definitions As Predictors of Future Good Radiographic + Functional Outcome in a Double-Blind, Phase 3, Randomized Controlled Trial of Tocilizumab
Martin J. Bergman¹, Jeffrey Yourish², Jinglan Pei², Jenny Devenport², William Reiss² and Edward Keystone³, ¹Taylor Hospital, Ridley Park, PA, ²Genentech, South San Francisco, CA, ³University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Based on treat-to-target guidelines, the goal of treatment should be remission. Definitions for remission recommended by the ACR/EULAR task force include joint counts and…
Abstract Number: 283 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Biologic Treatments In Juvenile Idiopathic Arthritis With a Polyarticular Course: An Indirect Comparison
Laura Sawyer¹, Alex Diamantopoulos², Hermine Brunner³, Fabrizio De Benedetti⁴, Nicolino Ruperto⁵, Fred Dejonckheere⁶ and Caroline Keane⁷, ¹Symmetron Limited, London, United Kingdom, ²Symmetron Limited, Herts, United Kingdom, ³PRCSG, Cincinnati, OH, ⁴Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵PRINTO, Genoa, Italy, ⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁷Roche, Welwyn Garden City, United Kingdom
Background/Purpose: To date there are no head-to-head trials comparing the efficacy of biologic treatments for polyarticular-course JIA (pcJIA). The purpose of this study was to…
Abstract Number: 2368 • 2012 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Takayasu’s Arteritis: 7 Patients Followed At a Single Italian Centre
Enrico Tombetti¹, Elena Baldissera², Stefano Franchini¹, Patrizia Aiello³, Francesca Motta¹, Barbara Gulgielmi¹ and Maria Grazia Sabbadini¹, ¹Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy, ²Vita-Salute San Raffaele University, Milano, Italy, ³Internal Medicine and Clinical Immunology, Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milano, Italy
Background/Purpose: Takayasu arteritis (TA) is a rare chronic-relapsing vasculitis involving primarily the aorta and its major branches.TA is associated with considerable morbidity and mortality. Therapy…
Abstract Number: 455 • 2012 ACR/ARHP Annual Meeting
Lack of Additive Benefits of Concomitant Methotrexate Use to Tocilizumab Monotherapy for Rheumatoid Arthritis in Daily Clinical Practice
Keisuke Izumi¹, Yuko Kaneko², Hidekata Yasuoka³, Noriyuki Seta⁴, Hideto Kameda⁵, Masataka Kuwana⁵ and Tsutomu Takeuchi⁶, ¹Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ²Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine, Keio university, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Keio University School of Medicine, Tokyo, Japan
Background/Purpose: To explore the benefit of concomitant use of methotrexate (MTX) for the effectiveness of TCZ in rheumatoid arthritis (RA) patients in daily clinical practice.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].